RXi Pharmaceuticals Corp Stock Nasdaq
Equities
US74979C5013
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 75M 103M | Capitalization | 3.3M 4.52M |
---|---|---|---|---|---|
Net income 2024 * | -9M -12.35M | Net income 2025 * | 47M 64.49M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.04 x |
P/E ratio 2024 * |
-0.39
x | P/E ratio 2025 * |
0.19
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 17-09-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Director/Board Member | 73 | 22-05-01 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 13-04-17 |
1st Jan change | Capi. | |
---|---|---|
+48.54% | 56.61B | |
-6.02% | 39.62B | |
+37.12% | 39.25B | |
-6.90% | 28.28B | |
+12.97% | 26.44B | |
-16.91% | 20.12B | |
+28.18% | 12.51B | |
+31.71% | 12.48B | |
+0.38% | 12.2B |